GlobalData on MSN9d
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...
Valneva Receives Marketing Authorization In The UK For The World’S First Chikungunya Vaccine, IXCHIQ®
February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
Business Insider10d
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA) 5, the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ...
Pharmabiz8d
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
Valneva submitted label extension applications to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada to potentially extend the use of Ixchiq to ...
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...
Seeking Alpha9d
Valneva rises after U.K. approval of chikungunya vaccine
Valneva (NASDAQ:VALN) has already submitted regulatory filings in all three jurisdictions seeking label expansions to market Ixchiq for adolescents aged 12–17 years. The company expects to file ...
Yahoo Finance9d
Valneva’s chikungunya vaccine wins UK approval
France-based Valneva has also submitted label extension applications in the US, EU, and Canada, to expand the use of Ixchiq to patients aged 12 to 17, and now plans to do the same in the UK.